ASCO 2014

 
 
 

Photo by ASCO/Rodney White 2014

The 50th Annual Meeting of the American Society of Clinical Oncology took place May 30 - June 3 in Chicago, Illinois.

 

Ruxolitinib improves disease control in PV

Mark Fuerst Read Article
Published: 06/23/14

ASCO_2014_attendees_ASCO_Phil McCarten_230.jpg
Session at ASCO 2014
©ASCO/Phil McCarten

The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV) who cannot tolerate or are resistant to hydroxyurea, according to a speaker at the 2014 ASCO Annual Meeting. Results of the phase 3 RESPONSE trial showed that ruxolitinib can reduce spleen size in these patients and improve hematocrit control without the need for phlebotomy. And the drug was generally well-tolerated. [Read Article]

Treating HIV+ lymphoma patients

HT Staff Read Article
Published: 06/23/14

ASCO_2014_stairs_ASCO-Brian_Powers_230.jpg
Attendees at ASCO 2014
©ASCO/Brian Powers

Hepatitis C reactivation does not worsen survival outcomes for HIV-positive patients diagnosed with lymphoma, new research indicates. The study showed these patients can tolerate chemotherapy without adverse outcomes and are therefore eligible for aggressive treatment. They should be closely monitored, however, according to study investigator Stefan K. Barta, MD, of Fox Chase Cancer Center in Philadelphia, Pennsylvania. [Read Article]

Elderly males with DLBCL require increased rituximab dosing

Mark Fuerst Read Article
Published: 06/20/14

ASCO_attendees_theatre_ASCO_Phil_McCarten_230.jpg
Attendees at ASCO 2014
©ASCO/Phil McCarten

Elderly males with non-Hodgkin lymphoma (NHL) may require one-third higher doses of rituximab than the current standard to attain optimal responses to rituximab-containing chemotherapy, a new study suggests. Increasing the rituximab dose eliminated any gender-related differences in survival among elderly patients with aggressive, CD20+, B-cell lymphomas, said investigator Michael Pfreundschuh, MD, of Saarland University Medical Center in Germany.  [Read Article]

Switch to nilotinib improves deep molecular response in CML

Mark Fuerst Read Article
Published: 06/19/14

audience_ASCO_2014_Credit_ASCO_hil_McCarten_230.jpg
Audience at ASCO 2014
©ASCO/Phil McCarten

Patients with chronic myeloid leukemia (CML) are more likely to achieve a deep molecular response if they switch to nilotinib rather than remain on imatinib, updated research suggests. Patients with detectable disease who crossed over from imatinib to nilotinib after 24 months on the ENESTcmr study were able to achieve deep molecular responses (MR 4.5) by 36 months. But none of the patients who remained on imatinib achieved undetectable BCR-ABL transcripts. [Read Article]

CNS involvement predicts relapse but not survival in ARL, study shows

HT Staff Read Article
Published: 06/18/14

ASCO_2014_posters_ASCO-Todd Buchanan_230.jpg
Posters at ASCO 2014
©ASCO/Todd Buchanan

Investigators have found evidence to suggest that identifying central nervous system (CNS) involvement at diagnosis does not impact overall survival for patients with AIDS-related lymphoma (ARL). The research showed that ARL patients with CNS involvement at diagnosis were nearly 3 times as likely as their peers to have CNS relapse during cancer treatment. But there was no significant difference between the 2 groups with regard to survival.  [Read Article]

CAR T-cell therapy successfully used frontline as consolidation in CLL

Mark Fuerst Read Article
Published: 06/13/14

ASCO_2014__posters_Credit ASCO-Todd Buchanan 2014_230.jpg
Poster hall at ASCO 2014
©ASCO/Todd Buchanan

Infusion of autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells appears to have promising anti-tumor activity and be well-tolerated as a consolidation to frontline chemotherapy in patients with high-risk chronic lymphocytic leukemia (CLL), researchers report. In a phase 1 trial, the modified T cells benefitted 43% of patients, including 1 who achieved a complete response and 2 who achieved marrow responses only. [Read Article]

Lenalidomide combination improves QOL in newly diagnosed MM

Mark Fuerst Read Article
Published: 06/12/14

ASCO_2014_Info booth_Credit ASCO-Scott Morgan 2014_230.jpg
Info booth at ASCO 2014
© ASCO/Scott Morgan

Substituting lenalidomide for thalidomide in the standard treatment of newly diagnosed multiple myeloma (MM) improves quality of life and lowers toxicity without significant loss of response, results of a phase 3 study suggest. Combination melphalan, prednisone, and thalidomide (MPT) is considered a standard treatment option for transplant ineligible, newly diagnosed MM. Early phase 1/2 studies suggested substituting lenalidomide for thalidomide might result in similar efficacy and less toxicity. [Read Article]

Novel agent shows promising activity in heavily pretreated NHL

Mark Fuerst Read Article
Published: 06/11/14

ASCO_2014_Lobby_Credit ASCO-Rodney White 2014_230.jpg
Lobby view at ASCO 2014
©ASCO/Rodney White

The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as monotherapy to patients with heavily pretreated non-Hodgkin lymphoma (NHL), according to a presentation at the 2014 ASCO Annual Meeting. “Selinexor has favorable pharmacokinetic and pharmacodynamic characteristics,” said presenter Martin Gutierrez, MD, of the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}